Dr. Brian K. Yeh
Claim this profileMcLaren Cancer Institute-Macomb
Studies Prostate Adenocarcinoma
Studies Prostate Cancer
13 reported clinical trials
43 drugs studied
Affiliated Hospitals
Clinical Trials Brian K. Yeh is currently running
Monalizumab or Oleclumab with Durvalumab and Radiation
for Lung Cancer
This phase I trial studies the safety of adding durvalumab to accelerated hypofractionated radiation therapy (ACRT) or conventionally fractionated radiation therapy, as well as the safety of adding either monalizumab or oleclumab to durvalumab plus conventionally fractionated radiation therapy in treating patients with non-small cell lung cancer that has spread to nearby tissue or lymph nodes (locally advanced). Accelerated hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Immunotherapy with monoclonal antibodies, such as durvalumab and monalizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Oleclumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD73, which is found on some types of tumor cells. Oleclumab may block CD73 and help the immune system kill tumor cells. It is not yet known whether adding durvalumab to ACRT or adding monalizumab or oleclumab to durvalumab plus conventionally fractionated radiation therapy will work better in treating patients with non-small cell lung cancer.
Recruiting1 award Phase 110 criteria
Omitting Radiation Therapy
for Breast Cancer
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
More about Brian K. Yeh
Clinical Trial Related4 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Brian K. Yeh has experience with
- Radiation Therapy
- Flutamide
- Intensity-Modulated Radiation Therapy
- Apalutamide
- Atezolizumab
- Cisplatin
Breakdown of trials Brian K. Yeh has run
Prostate Adenocarcinoma
Prostate Cancer
Lung Cancer
Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Brian K. Yeh specialize in?
Brian K. Yeh focuses on Prostate Adenocarcinoma and Prostate Cancer. In particular, much of their work with Prostate Adenocarcinoma has involved treating patients, or patients who are undergoing treatment.
Is Brian K. Yeh currently recruiting for clinical trials?
Yes, Brian K. Yeh is currently recruiting for 8 clinical trials in Mount Clemens Michigan. If you're interested in participating, you should apply.
Are there any treatments that Brian K. Yeh has studied deeply?
Yes, Brian K. Yeh has studied treatments such as Radiation Therapy, Flutamide, Intensity-Modulated Radiation Therapy.
What is the best way to schedule an appointment with Brian K. Yeh?
Apply for one of the trials that Brian K. Yeh is conducting.
What is the office address of Brian K. Yeh?
The office of Brian K. Yeh is located at: McLaren Cancer Institute-Macomb, Mount Clemens, Michigan 48043 United States. This is the address for their practice at the McLaren Cancer Institute-Macomb.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.